Recombinant
RabMAb

Anti-HLA-DR antibody [EPR3691(2)] (ab124809)

Overview

  • Product name
    Anti-HLA-DR antibody [EPR3691(2)]
    See all HLA-DR primary antibodies
  • Description
    Rabbit monoclonal [EPR3691(2)] to HLA-DR
  • Tested applications
    Suitable for: WBmore details
    Unsuitable for: Flow Cyt,ICC,IHC-P or IP
  • Species reactivity
    Reacts with: Human
    Does not react with: Mouse, Rat
  • Immunogen

    corresponding to Human HLA-DR aa 100-200.

  • Positive control
    • Raji, Ramos, HuT-78 and Human spleen lysates
  • General notes

    This product is a recombinant rabbit monoclonal antibody.

    Produced using Abcam’s RabMAb® technology. RabMAb® technology is covered by the following U.S. Patents, No. 5,675,063 and/or 7,429,487.

Properties

  • Form
    Liquid
  • Storage instructions
    Shipped at 4°C. Store at -20°C. Stable for 12 months at -20°C.
  • Storage buffer
    PBS 49%,Sodium azide 0.01%,Glycerol 50%,BSA 0.05%
  • Purity
    Tissue culture supernatant
  • Clonality
    Monoclonal
  • Clone number
    EPR3691(2)
  • Isotype
    IgG
  • Research areas

Applications

Our Abpromise guarantee covers the use of ab124809 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
WB 1/1000 - 1/10000. Detects a band of approximately 35 kDa (predicted molecular weight: 29 kDa).
  • Application notes
    Is unsuitable for Flow Cyt,ICC,IHC-P or IP.
  • Target

    • Function
      Binds peptides derived from antigens that access the endocytic route of antigen presenting cells (APC) and presents them on the cell surface for recognition by the CD4 T-cells. The peptide binding cleft accommodates peptides of 10-30 residues. The peptides presented by MHC class II molecules are generated mostly by degradation of proteins that access the endocytic route, where they are processed by lysosomal proteases and other hydrolases. Exogenous antigens that have been endocytosed by the APC are thus readily available for presentation via MHC II molecules, and for this reason this antigen presentation pathway is usually referred to as exogenous. As membrane proteins on their way to degradation in lysosomes as part of their normal turn-over are also contained in the endosomal/lysosomal compartments, exogenous antigens must compete with those derived from endogenous components. Autophagy is also a source of endogenous peptides, autophagosomes constitutively fuse with MHC class II loading compartments. In addition to APCs, other cells of the gastrointestinal tract, such as epithelial cells, express MHC class II molecules and CD74 and act as APCs, which is an unusual trait of the GI tract. To produce a MHC class II molecule that presents an antigen, three MHC class II molecules (heterodimers of an alpha and a beta chain) associate with a CD74 trimer in the ER to form an heterononamer. Soon after the entry of this complex into the endosomal/lysosomal system where antigen processing occurs, CD74 undergoes a sequential degradation by various proteases, including CTSS and CTSL, leaving a small fragment termed CLIP (class-II-associated invariant chain peptide). The removal of CLIP is facilitated by HLA-DM via direct binding to the alpha-beta-CLIP complex so that CLIP is released. HLA-DM stabilizes MHC class II molecules until primary high affinity antigenic peptides are bound. The MHC II molecule bound to a peptide is then transported to the cell membrane surface. In B-cells, the interaction between HLA-DM and MHC class II molecules is regulated by HLA-DO. Primary dendritic cells (DCs) also to express HLA-DO. Lysosomal miroenvironment has been implicated in the regulation of antigen loading into MHC II molecules, increased acidification produces increased proteolysis and efficient peptide loading.
    • Sequence similarities
      Belongs to the MHC class II family.
      Contains 1 Ig-like C1-type (immunoglobulin-like) domain.
    • Post-translational
      modifications
      Ubiquitinated by MARCH1 or MARCH8 at Lys-244 leading to down-regulation of MHC class II. When associated with ubiquitination of the beta subunit of HLA-DR: HLA-DRB4 'Lys-254', the down-regulation of MHC class II may be highly effective.
    • Cellular localization
      Cell membrane. Endoplasmic reticulum membrane. Golgi apparatus > trans-Golgi network membrane. Endosome membrane. Lysosome membrane. Late endosome membrane. The MHC class II complex transits through a number of intracellular compartments in the endocytic pathway until it reaches the cell membrane for antigen presentation.
    • Information by UniProt
    • Database links
    • Alternative names
      • DR alpha chain antibody
      • DR alpha chain precursor antibody
      • DRA_HUMAN antibody
      • DRB1 antibody
      • DRB4 antibody
      • Histocompatibility antigen HLA DR alpha antibody
      • HLA class II histocompatibility antigen antibody
      • HLA class II histocompatibility antigen DR alpha chain antibody
      • HLA DR1B antibody
      • HLA DR3B antibody
      • HLA DRA antibody
      • HLA DRA1 antibody
      • HLA DRB1 antibody
      • HLA DRB3 antibody
      • HLA DRB4 antibody
      • HLA DRB5 antibody
      • HLA-DRA antibody
      • HLADR4B antibody
      • HLADRA1 antibody
      • HLADRB antibody
      • Major histocompatibility complex class II DR alpha antibody
      • Major histocompatibility complex class II DR beta 1 antibody
      • Major histocompatibility complex class II DR beta 3 antibody
      • Major histocompatibility complex class II DR beta 4 antibody
      • Major histocompatibility complex class II DR beta 5 antibody
      • MGC117330 antibody
      • MHC cell surface glycoprotein antibody
      • MHC class II antigen DRA antibody
      • MHC II antibody
      • MLRW antibody
      see all

    Anti-HLA-DR antibody [EPR3691(2)] images

    • All lanes : Anti-HLA-DR antibody [EPR3691(2)] (ab124809) at 1/1000 dilution

      Lane 1 : Raji lysate
      Lane 2 : Ramos lysate
      Lane 3 : HuT-78 lysate
      Lane 4 : Human spleen lysate

      Lysates/proteins at 10 µg per lane.

      Secondary
      HRP labelled goat anti-rabbit at 1/2000 dilution

      Predicted band size : 29 kDa
      Observed band size : 35 kDa (why is the actual band size different from the predicted?)

    References for Anti-HLA-DR antibody [EPR3691(2)] (ab124809)

    ab124809 has not yet been referenced specifically in any publications.

    Product Wall

    Thank you for contacting us.
    I assume you were refering to ab107604 as the L243 antibody (http://www.abcam.com/hla-dr-antibody-l243-phycoerythrin-ab107604.html)? This antibody has not been tested in WB yet and is PE-conjugated. Please feel free to...

    Read More

    Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"

    Sign up